Leem is comprised of decision-making bodies (General Assembly, Board of Directors, Board President) and research bodies (Committees, Board, strategic implemention agencies).
Over 300 drug companies operate in France. They employ nearly 100,000 people and creat 550 new jobs per year while invest annually approximately 3.9 billion euros in research of new drugs.
The companies represented by the Leem realize 98.7% of the activity of the drug in France.
Worldwide (USA, Europe and Japan), more than 60 billion euros are spent each year by pharmaceutical companies to research and develop innovative new treatments. Drug companies are dedicated to creating and developing new medicines and vaccines for human use, for serious diseases related to the welfare and conditions of everyday life. The role of Leem is to develop and enforce the ethics of the profession, to facilitate trade between its members, to defend their collective interests and to strengthen links with other health professions.
Address: 58 Boulevard Gouvion Saint-Cyr, 75017 – Paris
Tel: +33 (0)1 45 03 88 88
Web: http://www.leem.org/
Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds of change in the sector after the establishment of the Macron government, the 2018 Strategic…
The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair…
The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up?…
What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop,…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
FEFIS represents 11 different associations across the industry with a very broad scope. How does the organization represent all of these different sectors? FEFIS represents as much as possible activities…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
Pharmaceuticals and Chemicals are inextricably linked industries which is evident through your board membership that is half comprised of chemical companies developing products for the pharmaceutical sector. To what degree…
France yet today you work for a foreign multinational within France. Can you speak to the differences in culture and what the transition has been like? I have spent half…
See our Cookie Privacy Policy Here
